Compare ClearPoint Neuro Inc (CLPT) vs Starbucks Corp (SBUX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
ClearPoint Neuro Inc vs Starbucks Corp — how do they compare? ClearPoint Neuro Inc trades at $15.85 (market cap $478.63M), while Starbucks Corp trades at $106.19 (market cap $121.00B). The key difference: Starbucks Corp is far larger — about 252.8× ClearPoint Neuro Inc's market cap, and Starbucks Corp pays a 2.34% dividend while ClearPoint Neuro Inc pays none. Which is the better fit depends on your goals.
| CLPT | SBUX | |
|---|---|---|
Market Cap | $478.63M | $121.00B |
Sector | Health | Consumer Cyclical |
52-Week High | $29.60 | $107.34 |
52-Week Low | $8.66 | $78.46 |
Enterprise Value | $506.63M | $143.69B |
Volume | — | 7,493,833 |
Dividend Yield | — | 2.34% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ClearPoint Neuro (CLPT) trades at $16.51, down 5.66% on the day, with a bullish technical signal from moving averages but negative profitability. The company reported record Q1 2026 revenue of $36.97M with 25% organic device growth, though it missed EPS estimates with a $0.32 loss. Recent FDA clearance for the Velocity Alpha surgical drill and a partnership with Sungkyunkwan University highlight expansion efforts in neurosurgical navigation and drug delivery.
Outlook remains speculative with 100% analyst buy ratings anticipating gene therapy commercialization upside, but high execution and regulatory risks persist amid consistent losses and negative margins. The stock's valuation at 11.31x sales reflects growth expectations, yet cash burn from operations requires careful monitoring of financing sustainability.
Starbucks (SBUX) trades at $107.34, up 1.25% on the day, with a bullish technical signal from moving averages and near the consensus price target of $108.31. Recent Q2 2026 results showed revenue of $9.53B and EPS beat expectations, while the company focuses on cost-cutting through AI initiatives. The stock exhibits strong support at $107 and faces resistance at $108.
The outlook is cautiously optimistic with analyst consensus leaning buy (47.46%), but high P/E of 81.94 and declining net income margins pose valuation concerns. Key risks include execution of AI cost savings and competitive pressures, while dividend growth and loyalty program strength offer stability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ClearPoint Neuro Inc
ClearPoint Neuro provides medical devices and software for precise neurosurgical procedures. Its navigation systems allow surgeons to perform minimally invasive brain and spine surgeries with extreme accuracy.
Read more on CLPT →About Starbucks Corp
Starbucks Corporation retails, roasts, and provides its own brand of specialty coffee. The Company operates retail locations worldwide and sells whole bean coffees through its sales group, direct response business, supermarkets, and on the world wide web. Starbucks also produces and sells bottled coffee drinks and a line of ice creams.
Read more on SBUX →
